Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF

What Was Tested

Researchers studied hCG (human chorionic gonadotropin) in this randomized controlled trial publication.

A comparative prospective and randomized study was conducted to investigate the effect of continuous administration of GnRH agonist during the luteal phase in an ovarian stimulation programme for IVF.

Why It Was Studied

It has been reported that ceasing the administration of gonadotrophin-releasing hormone (GnRH) agonist causes a profound suppression of circulating serum gonadotrophins.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this hCG (human chorionic gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

GnRH agonist was administered intranasally from the midluteal phase of the previous cycle, and pure FSH administration started on cycle day 7.

In the continuous-long protocol (cL) group (n = 161 ), GnRH agonist administration was continued until 14 days after oocyte retrieval.

In the long protocol (L) group (n = 158 ), GnRH agonist was administered until the day before human chorionic gonadotrophin (HCG) administration.

What Was Measured

The subject headings attached to it are Chorionic Gonadotropin, Embryo Implantation, Embryo Transfer, Fertilization in Vitro, Follicle Stimulating Hormone, Gonadotropin-Releasing Hormone and Luteal Phase.

What This Means in Plain Language

The paper is a randomized study of hCG (human chorionic gonadotropin).

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Human reproduction (Oxford, England)), a journal based in England.

More context: the hCG (human chorionic gonadotropin) compound page.